These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

219 related items for PubMed ID: 32056461

  • 21. Dual PI3K/mTOR inhibitor NVP-BEZ235 sensitizes docetaxel in castration resistant prostate cancer.
    Yasumizu Y, Miyajima A, Kosaka T, Miyazaki Y, Kikuchi E, Oya M.
    J Urol; 2014 Jan; 191(1):227-34. PubMed ID: 23954373
    [Abstract] [Full Text] [Related]

  • 22. Arenobufagin, a natural bufadienolide from toad venom, induces apoptosis and autophagy in human hepatocellular carcinoma cells through inhibition of PI3K/Akt/mTOR pathway.
    Zhang DM, Liu JS, Deng LJ, Chen MF, Yiu A, Cao HH, Tian HY, Fung KP, Kurihara H, Pan JX, Ye WC.
    Carcinogenesis; 2013 Jun; 34(6):1331-42. PubMed ID: 23393227
    [Abstract] [Full Text] [Related]

  • 23. The synergistic antitumor effect of IL-6 neutralization with NVP-BEZ235 in hepatocellular carcinoma.
    Wang Y, Miao X, Jiang Y, Wu Z, Zhu X, Liu H, Wu X, Cai J, Ding X, Gong W.
    Cell Death Dis; 2022 Feb 14; 13(2):146. PubMed ID: 35165269
    [Abstract] [Full Text] [Related]

  • 24. Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.
    Cui SX, Shi WN, Song ZY, Wang SQ, Yu XF, Gao ZH, Qu XJ.
    Oncotarget; 2016 Jun 14; 7(24):36767-36782. PubMed ID: 27167344
    [Abstract] [Full Text] [Related]

  • 25. Activity of the mTOR inhibitor RAD001, the dual mTOR and PI3-kinase inhibitor BEZ235 and the PI3-kinase inhibitor BKM120 in hepatocellular carcinoma.
    Kirstein MM, Boukouris AE, Pothiraju D, Buitrago-Molina LE, Marhenke S, Schütt J, Orlik J, Kühnel F, Hegermann J, Manns MP, Vogel A.
    Liver Int; 2013 May 14; 33(5):780-93. PubMed ID: 23489999
    [Abstract] [Full Text] [Related]

  • 26. pH-sensitive polymeric nanoparticles for co-delivery of doxorubicin and curcumin to treat cancer via enhanced pro-apoptotic and anti-angiogenic activities.
    Zhang J, Li J, Shi Z, Yang Y, Xie X, Lee SM, Wang Y, Leong KW, Chen M.
    Acta Biomater; 2017 Aug 14; 58():349-364. PubMed ID: 28455219
    [Abstract] [Full Text] [Related]

  • 27. A novel multitarget kinase inhibitor BZG with potent anticancer activity in vitro and vivo enhances efficacy of sorafenib through PI3K pathways in hepatocellular carcinoma cells.
    Wang L, Zhan Y, Wu Z, Lin M, Jin X, Jiang L, Qiu Y.
    Biomed Pharmacother; 2020 May 14; 125():110033. PubMed ID: 32187962
    [Abstract] [Full Text] [Related]

  • 28. Apolipoprotein E Peptide-Guided Disulfide-Cross-Linked Micelles for Targeted Delivery of Sorafenib to Hepatocellular Carcinoma.
    Li Y, Wei J, Wei Y, Cheng L, Guo B, Meng F, Li F, Zhong Z.
    Biomacromolecules; 2020 Feb 10; 21(2):716-724. PubMed ID: 31809037
    [Abstract] [Full Text] [Related]

  • 29. A reduction and pH dual-sensitive nanodrug for targeted theranostics in hepatocellular carcinoma.
    Cai M, Li B, Lin L, Huang J, An Y, Huang W, Zhou Z, Wang Y, Shuai X, Zhu K.
    Biomater Sci; 2020 Jun 21; 8(12):3485-3499. PubMed ID: 32432234
    [Abstract] [Full Text] [Related]

  • 30. A polymeric nanoformulation improves the bioavailability and efficacy of sorafenib for hepatocellular carcinoma therapy.
    Chen Y, Li JX, Shu N, Zheng SJ, Ma M, Zhao ZB, Cao ZT, Zhou Q, Du JZ, Wang J.
    Biomater Sci; 2021 Apr 07; 9(7):2508-2518. PubMed ID: 33459733
    [Abstract] [Full Text] [Related]

  • 31. Dual PI3K/mTOR inhibitor BEZ235 as a promising therapeutic strategy against paclitaxel-resistant gastric cancer via targeting PI3K/Akt/mTOR pathway.
    Chen D, Lin X, Zhang C, Liu Z, Chen Z, Li Z, Wang J, Li B, Hu Y, Dong B, Shen L, Ji J, Gao J, Zhang X.
    Cell Death Dis; 2018 Jan 26; 9(2):123. PubMed ID: 29374144
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. BEZ235 increases sorafenib inhibition of hepatocellular carcinoma cells by suppressing the PI3K/AKT/mTOR pathway.
    Li A, Zhang R, Zhang Y, Liu X, Wang R, Liu J, Liu X, Xie Y, Cao W, Xu R, Ma Y, Cai W, Wu B, Cai S, Tang X.
    Am J Transl Res; 2019 Jan 26; 11(9):5573-5585. PubMed ID: 31632530
    [Abstract] [Full Text] [Related]

  • 34. Inhibition of DNA methyltransferase as a novel therapeutic strategy to overcome acquired resistance to dual PI3K/mTOR inhibitors.
    Qian XJ, Li YT, Yu Y, Yang F, Deng R, Ji J, Jiao L, Li X, Wu RY, Chen WD, Feng GK, Zhu XF.
    Oncotarget; 2015 Mar 10; 6(7):5134-46. PubMed ID: 25762617
    [Abstract] [Full Text] [Related]

  • 35. Co-administration of combretastatin A4 nanoparticles and sorafenib for systemic therapy of hepatocellular carcinoma.
    Wang Y, Yu H, Zhang D, Wang G, Song W, Liu Y, Ma S, Tang Z, Liu Z, Sakurai K, Chen X.
    Acta Biomater; 2019 Jul 01; 92():229-240. PubMed ID: 31100462
    [Abstract] [Full Text] [Related]

  • 36. Therapeutic Effect of Sorafenib-Loaded TPGS-b-PCL Nanoparticles on Liver Cancer.
    Tang X, Lyu Y, Xie D, Li A, Liang Y, Zheng D.
    J Biomed Nanotechnol; 2018 Feb 01; 14(2):396-403. PubMed ID: 31352936
    [Abstract] [Full Text] [Related]

  • 37. A dual-targeting reconstituted high density lipoprotein leveraging the synergy of sorafenib and antimiRNA21 for enhanced hepatocellular carcinoma therapy.
    Li M, Su Y, Zhang F, Chen K, Xu X, Xu L, Zhou J, Wang W.
    Acta Biomater; 2018 Jul 15; 75():413-426. PubMed ID: 29859368
    [Abstract] [Full Text] [Related]

  • 38. Co-delivery of plantamajoside and sorafenib by a multi-functional nanoparticle to combat the drug resistance of hepatocellular carcinoma through reprograming the tumor hypoxic microenvironment.
    Zan Y, Dai Z, Liang L, Deng Y, Dong L.
    Drug Deliv; 2019 Dec 15; 26(1):1080-1091. PubMed ID: 31735093
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Topical application of a dual PI3K/mTOR inhibitor prevents anal carcinogenesis in a human papillomavirus mouse model of anal cancer.
    Rademacher BL, Matkowskyj KA, LaCount ED, Carchman EH.
    Eur J Cancer Prev; 2019 Nov 15; 28(6):483-491. PubMed ID: 30888976
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.